PuSH - Publication Server of Helmholtz Zentrum München

26 Records found.
Zum Exportieren der Ergebnisse bitte einloggen.
Lay all publications on this page into basket
1.
Li, M.* et al.: Induction of porcine-specific regulatory T cells with high specificity and expression of IL-10 and TGF-1 using baboon-derived tolerogenic dendritic cells. Xenotransplantation 25:e12355 (2018)
2.
Li, M.* ; Eckl, J. ; Geiger, C. ; Schendel, D.J. & Pohla, H.: A novel and effective method to generate human porcine-specific regulatory T cells with high expression of IL-10, TGF-β1 and IL-35. Sci. Rep. 7:3974 (2017)
3.
Gassenmaier, M.* et al.: CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis. Stem Cells 31, 1467-1476 (2013)
4.
Pohla, H. et al.: High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination. Mol. Med. 18, 1499-1508 (2013)
5.
Tschöp-Lechner, K. et al.: Modified vaccinia virus Ankara delivers a robust surrogate marker for immune monitoring to sarcoma cells even if cells are being exposed to chemotherapy and heat treatment. Int. J. Hyperthermia 28, 33-42 (2012)
6.
Walter, S.* et al.: Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. J. Nat. Med. 18, 1254-1261 (2012)
7.
Westermann, J.* et al.: Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: A clinical phase-I study. Gene Ther. 18, 354-363 (2011)
8.
Buchner, A.* et al.: Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma. Hum. Gene Ther. 21, 285-297 (2010)
9.
Brill, T.H.* et al.: Therapeutic vaccination with an Interleukon-2-Iinterferon-γ-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer - a phase I/II trial. Hum. Gene Ther. 20, 1-11 (2009)
10.
Geiger, C. et al.: Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma. J. Mol. Med. 87, 595-612 (2009)
11.
Wilde, S. et al.: Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Blood 114, 2131-2139 (2009)
12.
Ebelt, K. et al.: Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate 68, 1-10 (2008)
13.
Kutscher, S. et al.: The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT. Aids Res. Ther. 5:22 (2008)
14.
Brill, T.H.* et al.: Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial. J. Gene Med. 9, 547-560 (2007)
15.
Rüttinger, D.* et al.: Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: First clinical experience and evidence of an immune response. J. Transl. Med. 5:43 (2007)
16.
Zobywalski, A. et al.: Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J. Transl. Med. 5:18 (2007)
17.
Rüttinger, D.* et al.: Immunotherapy of lung cancer: An update. Onkologie 29, 33-38 (2006)
18.
Schleypen, J.S. et al.: Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin. Cancer Res. 12, 718-725 (2006)
19.
Frankenberger, B. et al.: Cell-based vaccines for renal cell carcinoma: Genetically-engineered tumor cells and monocyte-derived dendritic cells. World J. Urol. 23, 166-174 (2005)
20.
Frankenberger, B. et al.: Influence of CD80 Interleukin2, and Interleukin-7 Expression in Human Renal Cell Carcinoma on the Expression, Function, and Survival of Tumor-Specific CTLs. Clin. Cancer Res. 11, 1733-1742 (2005)